At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Nov 9, 2026 at 07:00 ET
Ocular Therapeutix reported Q3 2026 net loss of $(0.42) per share on revenue of $12.9M, missing the consensus EPS estimate of $(0.35) and revenue estimate of $14.3M. The company reiterated its AXPAXLI NDA submission for wet AMD is on track for Q4 2026, with $530.6M cash providing runway into 2028.
- Q3 2026 net loss $(94.8)M or $(0.42)/share vs consensus $(0.35)/share
- Q3 2026 total revenue $12.9M vs consensus $14.3M and prior year $14.5M
- Cash balance $530.6M as of Sep 30, 2026, expected runway into 2028
- AXPAXLI NDA submission for wet AMD on track for Q4 2026 under 505(b)(2) pathway
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access